close

Agreements

Date: 2018-12-04

Type of information: Resignation

Compound:

Company: Lundbeck (Denmark)

Therapeutic area:

Type agreement: resignation

Action mechanism:

Disease:

Details:

  • • On December 4, 2018, Lundbeck announced  that Anders Gersel Pedersen, Executive Vice President and Head of Research and Development (R&D), will retire after 19 years with the company. Anders Gersel’s retirement will be effective as of 31 December 2018. Anders Gersel Pedersen joined Lundbeck in 2000 as Vice President of International Clinical Research. Anders was later appointed Executive Vice President of Drug Development and in 2011 appointed responsible for all Research & Development activities at Lundbeck. Anders is a member of the European Society of Medical Oncology, the International Association for the Study of Lung Cancer, the American Society of Clinical Oncology, the Danish Society of Clinical Oncology and the Danish Society of Internal Medicine. He also serves on the Board of Directors at Bavarian Nordic (Deputy Chairman), Hansa Medical and Genmab.
  • Lundbeck has initiated a comprehensive international search to identify the company’s next EVP, Head of R&D.

Financial terms:

Latest news:

Is general: Yes